MA54870A - Pyrazolopyridines et triazolopyridines utilisées en tant qu'inhibiteurs a2a/a2b - Google Patents

Pyrazolopyridines et triazolopyridines utilisées en tant qu'inhibiteurs a2a/a2b

Info

Publication number
MA54870A
MA54870A MA054870A MA54870A MA54870A MA 54870 A MA54870 A MA 54870A MA 054870 A MA054870 A MA 054870A MA 54870 A MA54870 A MA 54870A MA 54870 A MA54870 A MA 54870A
Authority
MA
Morocco
Prior art keywords
triazolopyridines
pyrazolopyridines
inhibitors
triazolopyridines used
Prior art date
Application number
MA054870A
Other languages
English (en)
Inventor
Taisheng Huang
xiaozhao Wang
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MA54870A publication Critical patent/MA54870A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
MA054870A 2019-01-29 2020-01-28 Pyrazolopyridines et triazolopyridines utilisées en tant qu'inhibiteurs a2a/a2b MA54870A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962798180P 2019-01-29 2019-01-29

Publications (1)

Publication Number Publication Date
MA54870A true MA54870A (fr) 2021-12-08

Family

ID=69771050

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054870A MA54870A (fr) 2019-01-29 2020-01-28 Pyrazolopyridines et triazolopyridines utilisées en tant qu'inhibiteurs a2a/a2b

Country Status (23)

Country Link
US (2) US11390624B2 (fr)
EP (1) EP3917925B1 (fr)
JP (1) JP7447128B2 (fr)
KR (1) KR20210133224A (fr)
CN (1) CN113906022A (fr)
AR (1) AR117900A1 (fr)
AU (1) AU2020215673A1 (fr)
BR (1) BR112021014865A2 (fr)
CA (1) CA3127939A1 (fr)
CL (1) CL2021001984A1 (fr)
CO (1) CO2021011253A2 (fr)
CR (1) CR20210456A (fr)
DK (1) DK3917925T3 (fr)
EA (1) EA202192093A1 (fr)
EC (1) ECSP21063186A (fr)
FI (1) FI3917925T3 (fr)
IL (1) IL285127A (fr)
MA (1) MA54870A (fr)
MX (1) MX2021009117A (fr)
PE (1) PE20212071A1 (fr)
SG (1) SG11202108180VA (fr)
TW (1) TWI829857B (fr)
WO (1) WO2020159905A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7474709B2 (ja) 2018-02-27 2024-04-25 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
GEP20237560B (en) 2018-07-05 2023-10-25 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2021138512A1 (fr) * 2020-01-03 2021-07-08 Incyte Corporation Polythérapie comprenant des inhibiteurs d'a2a/a2b et de pd-1/pd-l1
WO2023201267A1 (fr) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Polythérapie pour le traitement de cancers exprimant trop-2

Family Cites Families (272)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
DE19629378A1 (de) 1996-07-20 1998-01-29 Boehringer Ingelheim Kg Neue Triazolopurine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU743910B2 (en) 1997-03-24 2002-02-07 Kyowa Hakko Kirin Co., Ltd. {1,2,4}triazolo{1,5-c}pyrimidine derivatives
CN1152031C (zh) 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
CA2344828A1 (fr) 1998-09-22 2000-03-30 Tomoyuki Kanda Derives de ¬1,2,4|triazolo¬1,5-c|pyrimidine
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
IL146005A0 (en) 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
MXPA02001878A (es) 1999-08-23 2003-08-20 Dana Farber Cancer Inst Inc Moleculas b7-4 novedosas y usos de las mismas.
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
EP1286692A4 (fr) 2000-04-25 2004-11-17 Idec Pharma Corp Administration intrathecale de rituximab pour le traitement des lymphomes du systeme nerveux central
CZ303790B6 (cs) 2000-05-26 2013-05-09 Merck Sharp & Dohme Corp. Deriváty pyrimidinu a farmaceutický prostredek je obsahující
CA2413330A1 (fr) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Procede de broyage par voie humide
TWI319011B (en) 2001-01-17 2010-01-01 Intreat Pty Ltd Diagnosis and treatment of cancers and other conditions
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
WO2002096363A2 (fr) 2001-05-30 2002-12-05 Alteon, Inc. Methode de traitement de maladies fibreuses ou d'autres indications
JP2004536807A (ja) 2001-05-30 2004-12-09 アルテオン インコーポレイテッド 緑内障ｖの治療方法
AU2002337142B2 (en) 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
WO2003028732A1 (fr) 2001-09-28 2003-04-10 Kyowa Hakko Kogyo Co., Ltd. Antagoniste de recepteur
WO2003031587A2 (fr) 2001-10-09 2003-04-17 The Regents Of The University Of California Utilisation d'inhibiteurs de stat-6 comme agents therapeutiques
CA2462657C (fr) 2001-10-30 2011-04-26 Novartis Ag Derives de staurosporine inhibiteurs de l'activite tyrosine kinase du recepteur flt3
JP4488740B2 (ja) 2001-11-13 2010-06-23 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 免疫細胞活性化を調節する作用剤およびその使用方法
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
IL162721A0 (en) 2002-01-22 2005-11-20 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyridoÄ2,3-dÜpyrimidin-7-ones
JPWO2003068776A1 (ja) 2002-02-15 2005-06-02 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
EP1544200A1 (fr) 2002-09-24 2005-06-22 Kyowa Hakko Kogyo Co., Ltd. D riv de 1,2,4]-triazolo 1,5]pyrimidine
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2508660C (fr) 2002-12-23 2013-08-20 Wyeth Anticorps anti pd-1 et utilisations
EP2368578A1 (fr) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés
CA2510003A1 (fr) 2003-01-16 2004-08-05 Genentech, Inc. Banques de phages anticorps synthetiques
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
WO2004079013A1 (fr) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) utilisee dans le diagnostic et le traitement du cancer du pancreas
AU2004220225B2 (en) 2003-03-14 2010-06-17 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004092173A2 (fr) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Antagonistes de recepteur d'adenosine a2a
WO2004092172A2 (fr) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-c]pyrimidines et pyrazolo[1,5-c]pyrimidines et procedes de preparation et d'utilisation de celles-ci
UA99933C2 (ru) 2003-04-09 2012-10-25 Дженентек, Инк. Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
WO2004092177A1 (fr) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines et procedes de preparation et d'utilisation ce celles-ci
BRPI0411120A (pt) 2003-06-10 2006-07-18 Kyowa Hakko Kogyo Kk método para tratar de um distúrbio de ansiedade, composição, agente para tratar de um distúrbio de ansiedade, e, usos de um composto e de um derivado de xantina
WO2005003175A2 (fr) 2003-06-13 2005-01-13 Biogen Idec Ma Inc. Anticorps d'aglycosyle anti-cd154 (ligand cd40) et utilisations correspondantes
RU2376292C2 (ru) 2003-08-14 2009-12-20 Ф.Хоффманн-Ля Рош Аг Гамк-ергические модуляторы
CA2536408A1 (fr) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Anticorps ameliores possedant une fonction d'effecteur modifiee et procedes de fabrication associes
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
GB0403819D0 (en) 2004-02-20 2004-03-24 Merck Sharp & Dohme New compounds
DE602005015833D1 (de) 2004-03-19 2009-09-17 Warner Lambert Co Imidazopyridin- und imidazopyrimidin-derivate als antibakterielle mittel
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
MXPA06014247A (es) 2004-06-10 2007-03-12 Irm Llc Compuestos y composiciones como inhibidores de la proteina quinasa.
AU2005256963A1 (en) 2004-06-23 2006-01-05 Centre National De La Recherche Scientifique 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
US20050288502A1 (en) 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
CN101076807B (zh) 2004-10-15 2014-09-03 弗里塞恩公司 一次性密码验证的方法和系统
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US20060211739A1 (en) 2005-02-08 2006-09-21 Arturo Perez-Medrano Use of selective P2X7 receptor antagonists
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
WO2006125140A2 (fr) 2005-05-18 2006-11-23 Biogen Idec Inc. Methodes pour traiter des troubles fibrotiques
WO2006129626A1 (fr) 2005-05-30 2006-12-07 Kyowa Hakko Kogyo Co., Ltd. Procede de fabrication d'un derive de [1,2,4]triazolo[1,5-c]pyrimidine
EP2258372B8 (fr) 2005-06-07 2012-12-19 Kyowa Hakko Kirin Co., Ltd. L'utilisation des antagonistes des récepteurs A2A pour le treaitment de troubles de motricité
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
JP4986451B2 (ja) 2005-06-30 2012-07-25 信一郎 礒部 マーキング剤
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
WO2007011759A2 (fr) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibiteurs de la kinesine mitotique
EP1928237A4 (fr) 2005-09-02 2011-03-09 Abbott Lab Nouveaux heterocycles a base imidazo
RU2008122967A (ru) 2005-11-10 2009-12-20 Шеринг Корпорейшн (US) Имидазопиразины в качестве ингибиторов протеинкиназ
WO2007061737A2 (fr) 2005-11-17 2007-05-31 Osi Pharmaceuticals, Inc. INHIBITEURS mTOR BICYCLIQUES CONDENSES
EP1962853A1 (fr) 2005-12-22 2008-09-03 Alcon Research, Ltd. (indazol-5-yl)-pyrazines et (1,3-dihydro-indol-2-un)- pyrazines pour le traitement de maladies et de conditions a mediation de rho kinase
CA2680789C (fr) 2006-03-28 2016-02-16 Atir Holding S.A. Composes heterocycliques et leurs utilisations dans le traitement de troubles sexuels
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
PT2029602E (pt) 2006-05-31 2010-07-08 Galapagos Nv Compostos de triazolopirazina uteis para o tratamento de doenãas degenerativas e inflamatërias
CN101466714B (zh) 2006-06-23 2013-02-06 英赛特股份有限公司 作为hm74a激动剂的嘌呤酮衍生物
WO2008002490A2 (fr) 2006-06-23 2008-01-03 Radius Health, Inc. Traitement de symptômes vasomoteurs par des modulateurs des récepteurs d'œstrogène sélectifs
WO2008007648A1 (fr) 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
EP1889846A1 (fr) 2006-07-13 2008-02-20 Novartis AG Dérivés de purine comme agonistes du recepteur A2a
US20080021026A1 (en) 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
DE102006041292A1 (de) 2006-09-01 2008-03-06 Henkel Kgaa Wasserstoffperoxid-Aktivierung mit N-Heterocyclen
WO2008037607A1 (fr) 2006-09-25 2008-04-03 Basf Se Composés hétérocycliques à teneur en groupe carbonyle et leur utilisation pour lutter contre des champignons phytopathogènes
WO2008056176A1 (fr) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines utiles comme inhibiteurs de la phosphodiestérase
KR20090127867A (ko) 2006-12-05 2009-12-14 네이셔널 치아오 텅 유니버시티 인다졸 화합물
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CN103204852A (zh) 2007-04-10 2013-07-17 H.隆德贝克有限公司 作为p2x7拮抗剂的杂芳基酰胺类似物
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
WO2008138843A1 (fr) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyridines et triazolopyrimidines utiles pour le traitement de maladies dégénératives et inflammatoires des articulations
WO2008141239A1 (fr) 2007-05-10 2008-11-20 Acadia Pharmaceuticals Inc. Imidazole [1,2-a] pyridines et composés présentant une activité au niveau des récepteurs cb2 cannabinoïdes
HUP0700395A2 (en) 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
CA2855098C (fr) 2007-06-18 2018-02-27 Merck Sharp & Dohme B.V. Anticorps diriges contre le recepteur humain de mort programmee pd-1
CA2693232A1 (fr) 2007-07-18 2009-01-22 Novartis Ag Composes heteroaryliques bicycliques et leur utilisation comme inhibiteurs de kinase
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CN101842098A (zh) 2007-08-10 2010-09-22 基因实验室技术有限公司 用于治疗病毒感染的含氮的二环化学实体
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2211862A2 (fr) 2007-10-18 2010-08-04 Novartis AG Inhibiteurs csf-1r, compositions et procédés d'utilisation
US20090118301A1 (en) 2007-11-02 2009-05-07 Arbor Vita Corporation Compositions and Methods for Treating Cancer
CA2704645A1 (fr) 2007-11-09 2009-05-14 The Salk Institute For Biological Studies Inhibiteurs non nucleosidiques de la transcriptase inverse
PE20091074A1 (es) 2007-12-13 2009-07-26 Bayer Healthcare Ag Triazolotriazinas y triazolopirazinas y su uso
WO2009085185A1 (fr) 2007-12-19 2009-07-09 Amgen Inc. Composés condensés de pyridine, de pyrimidine et de triazine en tant qu'inhibiteurs du cycle cellulaire
PE20091268A1 (es) 2007-12-19 2009-09-19 Amgen Inc Derivados heterociclicos como inhibidores de pi3 quinasa
AU2009222047A1 (en) 2008-03-04 2009-09-11 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009117421A2 (fr) 2008-03-17 2009-09-24 Kalypsys, Inc. Modulateurs hétérocycliques de gpr119 pour le traitement d’une maladie
JP5620365B2 (ja) 2008-03-21 2014-11-05 エンソン インコーポレイテッド 多官能分子システムを用いた積層体への金属の接着促進
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EP2444403A1 (fr) 2008-04-18 2012-04-25 Shionogi Co., Ltd. Composé hétérocyclique doté d'une activité inhibitrice sur PI3K
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
ES2658892T3 (es) 2008-07-23 2018-03-12 Kyowa Hakko Kirin Co., Ltd. Agente terapéutico para la migraña
WO2010033906A2 (fr) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Induction efficace de cellules souches pluripotentes au moyen de composés à petite molécule
WO2010032874A1 (fr) 2008-09-19 2010-03-25 住友化学株式会社 Composition utilisée en milieu agricole
EP3530672B1 (fr) 2008-09-26 2024-05-01 Dana-Farber Cancer Institute, Inc. Anticorps humains anti-pd-1, pd-l1 et pd-l2 et leurs utilisations
SG10201708690SA (en) 2008-12-09 2017-12-28 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
EP2367823A1 (fr) 2008-12-23 2011-09-28 Abbott Laboratories Composés antiviraux
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
EP2210891A1 (fr) 2009-01-26 2010-07-28 Domain Therapeutics Nouveaux ligands du récepteur de l'adénosine et leurs utilisations
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
KR20100101054A (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
EP2464647B1 (fr) * 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindoles en tant qe modulateurs du recepteur btk et leur utilisation
EA026693B1 (ru) 2009-08-17 2017-05-31 Интелликайн ЭлЭлСи Производные бензоксазола и бензотиазола в качестве ингибиторов pi3-киназы
US20110105541A1 (en) 2009-10-29 2011-05-05 Jackson Paul F ALKYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2011060207A1 (fr) 2009-11-16 2011-05-19 Schering Corporation Composés tricycliques condensés possédant une activité antagoniste des récepteurs a2a de l'adénosine
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2011078143A1 (fr) 2009-12-22 2011-06-30 塩野義製薬株式会社 Dérivés de pyrimidine et composition pharmaceutique les contenant
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
EP2347769A1 (fr) 2010-01-20 2011-07-27 Glycotope GmbH Marqueurs de cellules souches de cancer et utilisations associées
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
ES2572387T3 (es) 2010-03-18 2016-05-31 Pasteur Institut Korea Compuestos anti-infecciosos
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
GB201007187D0 (en) 2010-04-29 2010-06-09 Iti Scotland Ltd Ubiquitination modulators
WO2011153588A1 (fr) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Inhibiteurs de polymérase virale
US20120083498A1 (en) 2010-06-17 2012-04-05 Fatah Kashanchi Modulators of Viral Transcription, and Methods and Compositions Therewith
CA2802344C (fr) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Anticorps di-specifiques anti-tim-3 et pd-1 pour immunotherapie dans des etats pathologiques immuns chroniques
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CA2809331C (fr) 2010-08-27 2018-09-25 Merck Patent Gmbh Derives triazolopyrazine
EP2955183A1 (fr) 2010-10-25 2015-12-16 G1 Therapeutics, Inc. Inhibiteurs de cdk
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
CN103619841B (zh) 2011-01-11 2017-03-29 桑诺维恩药品公司 杂芳基化合物及其使用方法
WO2012116237A2 (fr) 2011-02-23 2012-08-30 Intellikine, Llc Composés hétérocycliques et leurs utilisations
MY161199A (en) 2011-03-23 2017-04-14 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
US9029389B2 (en) 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
WO2012147890A1 (fr) 2011-04-27 2012-11-01 持田製薬株式会社 Nouveau dérivé d'azole
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
EP2604265A1 (fr) 2011-12-17 2013-06-19 Royal College of Surgeons in Ireland (RCSI) Antagonistes P2x7 en tant que traitement auxiliaire ou principal contre l'état de mal épileptique
WO2013106254A1 (fr) 2012-01-11 2013-07-18 Dow Agrosciences Llc Compositions pesticides et procédés qui leur sont associés
WO2013178572A1 (fr) 2012-05-30 2013-12-05 F. Hoffmann-La Roche Ag Composés triazolo en tant qu'inhibiteurs de pde10
BR112014030147B1 (pt) 2012-06-22 2019-10-15 Sumitomo Chemical Company, Limited Compostos heterocíclicos fundidos, composição e método para controlar pestes
CN104662002A (zh) 2012-07-27 2015-05-27 比亚尔-珀特拉和Ca股份公司 取代脲类化合物的合成方法
CA2890897A1 (fr) 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System Inhibition de l'heterodimerisation de hif-2a avec hif1.beta. (arnt)
WO2014126580A1 (fr) 2013-02-15 2014-08-21 Dow Agrosciences Llc Compositions pesticides et processus associés à celles-ci
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
WO2014153424A1 (fr) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Réduction de diabète chez des patients recevant des inhibiteurs de l'hmg-coa réductase (statines)
AU2014292888B2 (en) 2013-07-25 2018-03-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
WO2015157955A1 (fr) 2014-04-17 2015-10-22 Abbvie Inc. Inhibiteurs de tyrosine kinase de bruton (btk) hétérocyclique
WO2016007722A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
EP3166974A1 (fr) 2014-07-11 2017-05-17 Genentech, Inc. Anticorps anti-pd-l1 et leurs utilisations
WO2016057522A1 (fr) 2014-10-06 2016-04-14 Flatley Discovery Lab Composés triazolopyridine et méthodes pour le traitement de la fibrose kystique
EP3736294A3 (fr) 2014-10-10 2021-02-17 Innate Pharma Blocage de cd73
US20180030144A1 (en) 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
GB2537445A (en) 2014-11-10 2016-10-19 Medimmune Ltd Binding molecules specific for CD73 and uses thereof
JP6847037B2 (ja) 2014-11-11 2021-03-24 メディミューン リミテッド 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
CN113773388A (zh) 2014-11-21 2021-12-10 百时美施贵宝公司 抗cd73抗体及其用途
MA41090A (fr) 2014-12-03 2017-10-10 H Lundbeck As Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
HUE057027T2 (hu) 2015-02-12 2022-04-28 Nissan Chemical Corp Kondenzált heterociklusos vegyületek és peszticidek
UA121669C2 (uk) * 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
WO2016144703A1 (fr) 2015-03-06 2016-09-15 Pharmakea, Inc. Inhibiteurs fluorés de la lysyl oxydase-like 2 et utilisations desdits inhibiteurs
CN107660205B (zh) 2015-04-03 2021-08-27 因赛特公司 作为lsd1抑制剂的杂环化合物
KR20180093127A (ko) 2015-07-30 2018-08-20 마크로제닉스, 인크. Pd-1-결합 분자 및 그것의 사용 방법
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
EP3365340B1 (fr) 2015-10-19 2022-08-10 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
MX2018006207A (es) 2015-11-19 2018-09-05 Incyte Corp Compuestos heterociclicos como inmunomoduladores.
CN114805575A (zh) 2015-12-09 2022-07-29 科尔沃斯制药股份有限公司 人源化抗cd73抗体
US20170174671A1 (en) 2015-12-17 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
LT3394033T (lt) 2015-12-22 2021-03-10 Incyte Corporation Heterocikliniai junginiai, kaip imunomoduliatoriai
WO2017112917A1 (fr) 2015-12-24 2017-06-29 Corvus Pharmaceuticals, Inc. Méthodes de traitement du cancer
CO2018008799A2 (es) 2016-02-24 2018-09-20 Pfizer Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de jak
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
MX2018011105A (es) 2016-03-16 2018-11-22 Kura Oncology Inc Inhibidores sustituidos de menina-mll y metodos de uso.
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4137489A1 (fr) 2016-06-20 2023-02-22 Incyte Corporation Composés hétérocycliques en tant qu'immunomodulateurs
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
WO2018004478A1 (fr) 2016-06-29 2018-01-04 Hayat Kimya San. A. Ş. Procédé amélioré de production de tissu non tissé mou
EP3481869A4 (fr) 2016-07-11 2020-02-26 Corvus Pharmaceuticals, Inc. Anticorps anti-cd73
WO2018013789A1 (fr) 2016-07-14 2018-01-18 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
TWI750218B (zh) 2016-09-02 2021-12-21 美商賽克瑞恩醫療公司 sGC 刺激劑
KR20190091281A (ko) 2016-12-13 2019-08-05 아스텔라스세이야쿠 가부시키가이샤 항인간 cd73 항체
KR102466418B1 (ko) 2016-12-16 2022-11-14 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
MX2019007416A (es) 2016-12-22 2019-12-11 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
HRP20221216T1 (hr) 2016-12-22 2022-12-23 Incyte Corporation Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
WO2018119221A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Dérivés pyridine utilisés en tant qu'immunomodulateurs
WO2018119263A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Composés hétérocycliques utilisés en tant qu'inducteurs de l'internalisation de pd-l1
AR110740A1 (es) 2017-01-23 2019-05-02 Revolution Medicines Inc Compuestos bicíclicos como inhibidores alostéricos de shp2
KR20180093088A (ko) 2017-01-24 2018-08-20 아이-맵 항-cd73 항체 및 이것의 사용
CN108467386B (zh) * 2017-02-23 2020-11-17 江苏恒瑞医药股份有限公司 稠杂芳基取代的1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用
UA125592C2 (uk) * 2017-03-16 2022-04-27 Джянгсу Хенгруй Медісін Ко., Лтд. ПОХІДНА ГЕТЕРОАРИЛ[4,3-c]ПІРИМІДИН-5-АМІНУ, СПОСІБ ЇЇ ОТРИМАННЯ ТА ЇЇ МЕДИЧНІ ЗАСТОСУВАННЯ
EP3606962A4 (fr) 2017-04-04 2020-12-23 Corvus Pharmaceuticals, Inc. Méthodes de traitement des tumeurs à taux de cd73 élevés
PL3611174T3 (pl) 2017-04-07 2022-08-08 Medshine Discovery Inc. Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a
EP3630830A1 (fr) 2017-05-23 2020-04-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Nouvel anticorps anti-cd73 et utilisations associées
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2018237173A1 (fr) 2017-06-22 2018-12-27 Novartis Ag Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
EP3641812A1 (fr) 2017-06-22 2020-04-29 Novartis AG Molécules d'anticorps se liant à cd73 et leurs utilisations
AU2018294557A1 (en) 2017-06-30 2020-01-02 Ryvu Therapeutics S.A. Imidazo(1,2-a)pyrazine modulators of the adenosine A2A receptor
CN109535161B (zh) 2017-09-22 2021-09-03 江苏恒瑞医药股份有限公司 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用
MX2020004190A (es) 2017-10-24 2020-08-03 Bayer Ag Amidas de imidazopiridina sustituidas y su uso.
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
PE20211455A1 (es) 2018-01-31 2021-08-05 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
UY38096A (es) 2018-02-17 2019-07-31 Astrazeneca Ab Inhibidores de arginasa y sus métodos de uso
JP7474709B2 (ja) 2018-02-27 2024-04-25 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
WO2019170131A1 (fr) 2018-03-07 2019-09-12 复旦大学 Anticorps cd73 ciblé et conjugué anticorps-médicament, procédé de préparation associé et utilisations correspondantes
CR20200392A (es) 2018-03-09 2020-11-17 Agenus Inc Anticuerpos anti-cd73 y métodos de uso de los mismos
KR20200128542A (ko) 2018-03-09 2020-11-13 페인스 테라퓨틱스 인코포레이티드 항-cd73 항체 및 이의 용도
CR20200520A (es) 2018-03-30 2021-03-09 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
WO2019200256A1 (fr) 2018-04-12 2019-10-17 Bristol-Myers Squibb Company Thérapie combinée anticacner avec un antagoniste de cd73 et un antagoniste de l'axe pd-1/pd-l1
RS64188B1 (sr) 2018-05-11 2023-06-30 Incyte Corp Tetrahidro-imidazo[4,5-c]piridin derivati kao pd-l1 imunomodulatori
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
EP4349411A2 (fr) 2018-06-20 2024-04-10 Incyte Corporation Anticorps anti-pd-1 et leurs utilisations
GEP20237560B (en) 2018-07-05 2023-10-25 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
EP3820474A4 (fr) 2018-07-10 2022-03-23 Nikang Therapeutics, Inc. Composés se liant au récepteur de l'adénosine
JP2021534139A (ja) 2018-08-13 2021-12-09 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft モノアシルグリセロールリパーゼ阻害剤としての新規の複素環化合物
EP3837264A1 (fr) 2018-08-13 2021-06-23 F. Hoffmann-La Roche AG Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase
KR20210049120A (ko) 2018-08-22 2021-05-04 아스트라제네카 아베 아르기나제 저해제 및 이의 사용 방법
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
AR116315A1 (es) 2018-09-12 2021-04-21 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos de triazolo-pirimidina y usos de los mismos
CN113164443A (zh) 2018-09-26 2021-07-23 库拉肿瘤学公司 用多发性内分泌抑癌蛋白抑制剂治疗血液系统恶性肿瘤
CN111295384B (zh) 2018-10-10 2022-08-12 江苏豪森药业集团有限公司 双环类衍生物抑制剂、其制备方法和应用
UY38437A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
WO2020106560A1 (fr) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Composés amino-triazolopyrimidine et amino-triazolopyrazine substitués utilisés en tant qu'antagonistes de récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation
CN116003441A (zh) 2018-11-30 2023-04-25 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
KR20220066074A (ko) 2019-08-26 2022-05-23 인사이트 코포레이션 A2a / a2b 억제제로서의 트리아졸로피리미딘
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
KR20220101664A (ko) 2019-11-11 2022-07-19 인사이트 코포레이션 Pd-1/pd-l1 억제제의 염 및 결정질 형태
BR112022013236A2 (pt) 2020-01-03 2022-09-06 Incyte Corp Anticorpos anti-cd73 e usos dos mesmos
WO2021138512A1 (fr) 2020-01-03 2021-07-08 Incyte Corporation Polythérapie comprenant des inhibiteurs d'a2a/a2b et de pd-1/pd-l1
KR20230117573A (ko) 2020-11-06 2023-08-08 인사이트 코포레이션 Pd-1 및 pd-l1 억제제, 및 이의 염 및 결정형의 제조 방법
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
TW202241441A (zh) 2020-12-29 2022-11-01 美商英塞特公司 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法

Also Published As

Publication number Publication date
CA3127939A1 (fr) 2020-08-06
IL285127A (en) 2021-09-30
EA202192093A1 (ru) 2021-11-16
FI3917925T3 (fi) 2024-04-23
SG11202108180VA (en) 2021-08-30
CL2021001984A1 (es) 2022-02-04
WO2020159905A1 (fr) 2020-08-06
ECSP21063186A (es) 2021-11-18
AU2020215673A1 (en) 2021-08-12
CR20210456A (es) 2022-01-06
BR112021014865A2 (pt) 2021-10-05
JP2022518936A (ja) 2022-03-17
AR117900A1 (es) 2021-09-01
TWI829857B (zh) 2024-01-21
PE20212071A1 (es) 2021-10-26
EP3917925B1 (fr) 2024-03-13
JP7447128B2 (ja) 2024-03-11
MX2021009117A (es) 2021-10-13
US11390624B2 (en) 2022-07-19
US20200270244A1 (en) 2020-08-27
KR20210133224A (ko) 2021-11-05
EP3917925A1 (fr) 2021-12-08
CO2021011253A2 (es) 2021-11-19
DK3917925T3 (da) 2024-03-25
CN113906022A (zh) 2022-01-07
TW202043226A (zh) 2020-12-01
US20230033393A1 (en) 2023-02-02
US11884665B2 (en) 2024-01-30

Similar Documents

Publication Publication Date Title
MA54870A (fr) Pyrazolopyridines et triazolopyridines utilisées en tant qu'inhibiteurs a2a/a2b
MA52422A (fr) Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b
KR102161364B9 (ko) LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
ECSP19024046A (es) Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
DK3558990T3 (da) Tetrahydroimidazo[4,5-c]pyridinderivater som pd-l1 internaliseringsinducere
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA46470A (fr) 1h-imidazo[4,5-b]pyridin-2(3h)-ones substituées et leur utilisation en tant que modulateurs du récepteur glun2b
MA52593A (fr) 1h-pyrazolo[4,3-b]pyridines en tant qu'inhibiteurs pde1
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
PE20151894A1 (es) Composiciones y metodos de variantes de inhibidor tisular de la metaloproteinasa tipo tres (timp 3)
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
DK2970260T3 (da) Imidazo-[4,5-c]pyridin- og pyrrolo-[2,3-c]pyridinderivater som ssao-inhibitorer
DK3194388T3 (da) Imidazo[4,5-c]pyridin afledte ssao-inhibitorer
CL2015002304A1 (es) Formas del metil {4,6-diamino-2- [1- (2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato
CL2016001777A1 (es) Composición herbicida que contiene ácido 4-amino-3-cloro-6-(4-cloro-2-fluoro-3-metoxifenil) piridin-2-carboxílico o sus derivados, fluroxipir o sus derivados y fenoxiauxinas o sus derivados
MA50250A (fr) Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
MA54448A (fr) Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5
BR112016020181A8 (pt) composições de ácido lipoico éster colina e métodos de uso.
DK3347356T3 (da) Tricyclic forbundet pyridin-2-one-derivater og deres anvendelse som brd4-hæmmere
IL252578B (en) History of 1h- pyrazolo (3.4-c) [5.1] naphthyridine 4-(5h)-one and pharmaceutical preparations containing them
MA53432A (fr) Imidazo[1,2-b]pyridazines utilisées en tant qu'inhibiteurs de trk
MA49841A (fr) Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine